InVivo tumbles again, now off by two-thirds in four days

It's shaping up to be another ugly session for InVivo Therapeutics (NVIV.OB -28.5%) as doubts about the timeline and clinical plan for the company's biopolymer scaffolding persist.

The stock is now down 64% since Friday.

SA contributor and Zacks analyst Jason Napodano penned a cautious (but generally upbeat) piece on the shares Tuesday, noting that the "more realistic clinical guidance from the new interim CEO [is] refreshing."

Nevertheless, Napodano says he has been removed from the list of analysts on the company's website.

Comments (1)
  • Esekla
    , contributor
    Comments (4648) | Send Message
    Napodano's commentary on Twitter that morning had a very different tone, which may account for the removal. I go by the same name on Twitter.
    28 Aug 2013, 10:54 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs